{
    "id": 30471,
    "fullName": "EGFR A702V",
    "impact": "missense",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "EGFR A702V lies within a region of the Egfr protein important for dimerization, phosphorylation, and activation (UniProt.org). A702V is predicted to confer a gain of function to the Egfr protein, as demonstrated by greater than 24.5-fold growth advantage in IL-3-depeleted cells in culture, as compared to wild-type Egfr, and confirmed in additional assays (PMID: 30952700).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 15530,
                    "pubMedId": 30952700,
                    "title": "An unbiased in vitro screen for activating epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30952700"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "A702V",
    "createDate": "07/07/2019",
    "updateDate": "07/07/2019",
    "referenceTranscriptCoordinates": {
        "id": 180839,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55173964C>T",
        "cDna": "c.2105C>T",
        "protein": "p.A702V",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 17510,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) treatment of transformed mouse cells expressing Egfr A702V resulted in decreased cell viability (PMID: 30952700).",
            "molecularProfile": {
                "id": 32649,
                "profileName": "EGFR A702V"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15530,
                    "pubMedId": 30952700,
                    "title": "An unbiased in vitro screen for activating epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30952700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17511,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tarceva (erlotinib) treatment of transformed mouse cells expressing Egfr A702V did not prevent increased cell viability, indicating resistance of Egfr A702V (PMID: 30952700).",
            "molecularProfile": {
                "id": 32649,
                "profileName": "EGFR A702V"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15530,
                    "pubMedId": 30952700,
                    "title": "An unbiased in vitro screen for activating epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30952700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17509,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erbitux (cetuximab) treatment of transformed mouse cells expressing Egfr A702V resulted in decreased cell viability (PMID: 30952700).",
            "molecularProfile": {
                "id": 32649,
                "profileName": "EGFR A702V"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15530,
                    "pubMedId": 30952700,
                    "title": "An unbiased in vitro screen for activating epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30952700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 32649,
            "profileName": "EGFR A702V",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 180839,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55173964C>T",
            "cDna": "c.2105C>T",
            "protein": "p.A702V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}